BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12789874)

  • 21. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
    Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
    Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
    Diemunsch P; Korttila K; Leeser J; Helmers JH; Wilkey B; Navé S; Radke AJ; Hahne WF; Brown RA
    J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in preventing chemotherapy-induced nausea and vomiting.
    Markman M
    Cleve Clin J Med; 2002 Aug; 69(8):609-10, 612, 615-7. PubMed ID: 12184469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.
    del Giglio A; Soares HP; Caparroz C; Castro PC
    Cancer; 2000 Dec; 89(11):2301-8. PubMed ID: 11147601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
    Momper JD; Heinrichs MT; Krudys K; Griebel D; Kumar S; Kim I; Mehrotra N; Mulberg AE; Garimella N; Nelson R; Reaman G; Sinha V; Yao L; Zineh I; Burckart G; Sachs H; Mulugeta Y
    J Clin Pharmacol; 2020 Jun; 60(6):775-784. PubMed ID: 31967340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia.
    Keat CH; Ghani NA
    Asian Pac J Cancer Prev; 2013; 14(12):7701-6. PubMed ID: 24460356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
    Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
    Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.
    Janicki PK; Schuler HG; Jarzembowski TM; Rossi M
    Anesth Analg; 2006 Apr; 102(4):1127-33. PubMed ID: 16551910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of adjuvant lorazepam with granisetron on chemotherapy-induced nausea and vomiting in pediatric patients with acute lymphoblastic leukemia.
    Ono A; Kishimoto K; Hasegawa D; Goldman RD; Kosaka Y
    Support Care Cancer; 2019 Mar; 27(3):895-899. PubMed ID: 30066198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
    Danner K; Becker HG; Best B; Madler C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.